DK174413B1 - Vævsplasminogenaktivator, DNA til kodning deraf, rekombinant vektor, transformant, samt fremgangsmåde til fremstilling af en vævsplasminogenaktivator - Google Patents

Vævsplasminogenaktivator, DNA til kodning deraf, rekombinant vektor, transformant, samt fremgangsmåde til fremstilling af en vævsplasminogenaktivator Download PDF

Info

Publication number
DK174413B1
DK174413B1 DK198804319A DK431988A DK174413B1 DK 174413 B1 DK174413 B1 DK 174413B1 DK 198804319 A DK198804319 A DK 198804319A DK 431988 A DK431988 A DK 431988A DK 174413 B1 DK174413 B1 DK 174413B1
Authority
DK
Denmark
Prior art keywords
dna
plasmid
coli
plasminogen activator
amino acid
Prior art date
Application number
DK198804319A
Other languages
Danish (da)
English (en)
Other versions
DK431988D0 (da
DK431988A (da
Inventor
Mineo Niwa
Yoshimasa Saito
Hitoshi Sasaki
Masako Hayashi
Jouji Notani
Masakuzu Kobayashi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878718298A external-priority patent/GB8718298D0/en
Priority claimed from GB878725052A external-priority patent/GB8725052D0/en
Priority claimed from GB878726683A external-priority patent/GB8726683D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of DK431988D0 publication Critical patent/DK431988D0/da
Publication of DK431988A publication Critical patent/DK431988A/da
Application granted granted Critical
Publication of DK174413B1 publication Critical patent/DK174413B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198804319A 1987-08-03 1988-08-02 Vævsplasminogenaktivator, DNA til kodning deraf, rekombinant vektor, transformant, samt fremgangsmåde til fremstilling af en vævsplasminogenaktivator DK174413B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB878718298A GB8718298D0 (en) 1987-08-03 1987-08-03 Tissue plasminogen activator
GB8718298 1987-08-03
GB8725052 1987-10-26
GB878725052A GB8725052D0 (en) 1987-10-26 1987-10-26 Tissue plasminogen activator
GB878726683A GB8726683D0 (en) 1987-11-13 1987-11-13 Tissue plasminogen activator
GB8726683 1987-11-13

Publications (3)

Publication Number Publication Date
DK431988D0 DK431988D0 (da) 1988-08-02
DK431988A DK431988A (da) 1989-02-04
DK174413B1 true DK174413B1 (da) 2003-02-17

Family

ID=27263535

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198804319A DK174413B1 (da) 1987-08-03 1988-08-02 Vævsplasminogenaktivator, DNA til kodning deraf, rekombinant vektor, transformant, samt fremgangsmåde til fremstilling af en vævsplasminogenaktivator

Country Status (11)

Country Link
US (2) US5648250A (ja)
EP (1) EP0302456B1 (ja)
JP (3) JP2561708B2 (ja)
KR (1) KR970001237B1 (ja)
AT (1) ATE108206T1 (ja)
AU (1) AU623340B2 (ja)
CA (1) CA1341458C (ja)
DE (1) DE3850531T2 (ja)
DK (1) DK174413B1 (ja)
ES (1) ES2056082T3 (ja)
IL (1) IL87276A (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it
IL88247A0 (en) * 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
GB9204439D0 (en) 1992-02-27 1992-04-15 Fujisawa Pharmaceutical Co A new cephalosporin c acylase
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6821755B2 (en) * 2000-07-27 2004-11-23 Boehringer Ingelheim International Gmbh Preparation of a recombinant protein in a prokaryotic host cell
GB0027779D0 (en) * 2000-11-14 2000-12-27 Boehringer Ingelheim Int Methods for large scale production of recombinant dna-derived tpa or k2s molecules
US6955910B2 (en) 2000-11-14 2005-10-18 Boehringer Ingelheim International Gmbh Method for large scale production of recombinant DNA-derived TPA or K2S molecules
US7087412B2 (en) 2000-11-14 2006-08-08 Boehringer Ingelheim International Gmbh Methods for large scale protein production in prokaryotes
GB0029001D0 (en) * 2000-11-28 2001-01-10 Isis Innovation Assay
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
KR100855024B1 (ko) 2008-04-30 2008-08-28 가톨릭대학교 산학협력단 크링글 도메인 １ 및 ２ 로 이루어진 비-글리코실화 재조합단백질
EP2289542A1 (en) * 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
US4577584A (en) * 1984-12-24 1986-03-25 Shih Nan C Bell lock (II)
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8508717D0 (en) * 1985-04-03 1985-05-09 Beecham Group Plc Composition
EP0199574B1 (en) * 1985-04-22 1991-10-23 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
US5376547A (en) * 1987-01-30 1994-12-27 American Home Products Corporation Des-epidermal growth factor plasminogen activators
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
CA1341458C (en) 2004-10-12
AU623340B2 (en) 1992-05-14
US5840533A (en) 1998-11-24
JP2561708B2 (ja) 1996-12-11
DE3850531T2 (de) 1994-11-24
KR890003952A (ko) 1989-04-19
IL87276A (en) 1995-07-31
KR970001237B1 (ko) 1997-02-04
JP2606620B2 (ja) 1997-05-07
AU2036188A (en) 1989-02-09
EP0302456B1 (en) 1994-07-06
JP2570633B2 (ja) 1997-01-08
EP0302456A1 (en) 1989-02-08
JPH08228773A (ja) 1996-09-10
DE3850531D1 (de) 1994-08-11
DK431988D0 (da) 1988-08-02
ATE108206T1 (de) 1994-07-15
JPH07163346A (ja) 1995-06-27
ES2056082T3 (es) 1994-10-01
IL87276A0 (en) 1988-12-30
JPH01104167A (ja) 1989-04-21
US5648250A (en) 1997-07-15
DK431988A (da) 1989-02-04

Similar Documents

Publication Publication Date Title
DK174413B1 (da) Vævsplasminogenaktivator, DNA til kodning deraf, rekombinant vektor, transformant, samt fremgangsmåde til fremstilling af en vævsplasminogenaktivator
EP0405285B1 (en) Novel plasminogen activator
DK173910B1 (da) Ikke-glycosylerede polypeptider, som har en intakt lysin-isoleucin-binding i den position, der svarer til aminosyrerne 158-159 i det native prourokinasemolekyle, og som har tilstrækkeligt af den i fig. 4A og 4B viste aminosyresekvens til, ...
DK175938B1 (da) Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant
KR19990082479A (ko) 트롬빈 억제제에 대한 해독제인 트롬빈 돌연변이 단백질
US7070958B2 (en) Methods of making pro-urokinase mutants
WO1993003061A1 (en) Hematopoietic stem cell multiplier
AU612865B2 (en) A modified human psti
EP0241210B1 (en) Modified enzyme
NO175638B (ja)
EP0395375A1 (en) Novel DNA sequences which encode ancrod-like polypeptides and compositions comprising the expression products thereof
JPH0570364A (ja) 骨への破骨細胞付着を阻害する組成物及び方法
EP0379890A1 (en) New tissue plasminogen activator
CA2215531C (en) Mutant of the erythrina caffra type inhibitor and the use of the said mutant for purifying serin proteases
CA2185436C (en) Use of a recombinant inhibitor from erythrina caffra for purifying serine proteases
JPH0235084A (ja) トロンビン阻害物質の製造法
JPH05508771A (ja) Ａｎｃｒｏｄ類似蛋白質、その製造及び使用
BG60507B2 (bg) Човешки тъканен плазминогенен активатор
JPH0361482A (ja) 新規な組織プラスミノーゲン活性化因子
JPH0475584A (ja) ヒトプロウロキナーゼ様ポリペプチド及びその製造法
MXPA97007486A (en) Mutant of the type erythrina caffra inhibitor and the use of said mutant to purify proteases of being

Legal Events

Date Code Title Description
PUP Patent expired